Browsing Tag
CStone Pharmaceuticals
9 posts
CStone Pharmaceuticals unveils next-generation ADC pipeline at AACR 2025 as it shifts to proprietary innovation model
CStone Pharmaceuticals reveals powerful preclinical ADC data at AACR 2025, fueling investor interest in its next-gen oncology pipeline and IND filing momentum.
CStone targets European expansion with EMA filing for Sugemalimab in stage III NSCLC
CStone Pharmaceuticals seeks EMA approval for sugemalimab in stage III NSCLC, aiming to expand lung cancer immunotherapy options in Europe.
CStone advances CS5001 clinical trial for first-line DLBCL treatment in Australia
CStone Pharmaceuticals has taken a significant step in the development of its ROR1 antibody-drug conjugate with the submission…
CStone Pharmaceuticals advances CS2009 clinical trial, targeting multi-billion-dollar immunotherapy market
CStone Pharmaceuticals has officially commenced the Phase I clinical trial for CS2009, a cutting-edge PD-1/VEGF/CTLA-4 trispecific antibody, marking…
CStone Pharmaceuticals partners with SteinCares to expand cancer treatment in Latin America
CStone Pharmaceuticals, a leading biopharmaceutical company specializing in innovative cancer therapies, has entered a landmark partnership with SteinCares,…
CStone Pharmaceuticals advances cancer research with first-in-human clinical trial application for CS2009
CStone Pharmaceuticals, an innovation-driven biopharmaceutical company listed on the Hong Kong Stock Exchange (HKEX: 2616), has taken a…
CStone Pharmaceuticals receives positive CHMP opinion for Sugemalimab in NSCLC treatment
CStone Pharmaceuticals (HKEX: 2616), a leading innovation-driven biopharmaceutical company from China, announced a significant milestone with the Committee…
CStone’s sugemalimab gains CHMP recommendation for NSCLC treatment
CStone Pharmaceuticals has reached a pivotal milestone in its global strategy, with the Committee for Medicinal Products for…
CStone Pharmaceuticals strikes $480m worth oncology deal with Pfizer
US pharma giant Pfizer has entered into a collaboration deal worth up to $480 million with Chinese biopharma…